<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32304747
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1096-1186
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Pharmacological research
       </title>
       <isoabbreviation>
        Pharmacol. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Angiotensin Receptor Blockers and 2019-nCoV.
      </articletitle>
      <pagination>
       <medlinepgn>
        104832
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1043-6618(20)31140-3
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.phrs.2020.104832
      </elocationid>
      <abstract>
       <abstracttext>
        Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current 2019-nCoV pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for 2019-nCoV patients.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Saavedra
        </lastname>
        <forename>
         Juan M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington D.C. 20057, USA. Electronic address: juan.saavedra@georgetown.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Pharmacol Res
      </medlineta>
      <nlmuniqueid>
       8907422
      </nlmuniqueid>
      <issnlinking>
       1043-6618
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       Angiotensin Receptor Blockers
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of Competing Interest The author has no conflict of interest to declare with respect to this manuscript.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32304747
      </articleid>
      <articleid idtype="pii">
       S1043-6618(20)31140-3
      </articleid>
      <articleid idtype="doi">
       10.1016/j.phrs.2020.104832
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32302812
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1879-1026
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         726
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          11
         </day>
        </pubdate>
       </journalissue>
       <title>
        The Science of the total environment
       </title>
       <isoabbreviation>
        Sci. Total Environ.
       </isoabbreviation>
      </journal>
      <articletitle>
       Assessing nitrogen dioxide (NO
       <sub>
        2
       </sub>
       ) levels as a contributing factor to coronavirus (COVID-19) fatality.
      </articletitle>
      <pagination>
       <medlinepgn>
        138605
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0048-9697(20)32121-5
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.scitotenv.2020.138605
      </elocationid>
      <abstract>
       <abstracttext>
        Nitrogen dioxide (NO
        <sub>
         2
        </sub>
        ) is an ambient trace-gas result of both natural and anthropogenic processes. Long-term exposure to NO
        <sub>
         2
        </sub>
        may cause a wide spectrum of severe health problems such as hypertension, diabetes, heart and cardiovascular diseases and even death. The objective of this study is to examine the relationship between long-term exposure to NO
        <sub>
         2
        </sub>
        and coronavirus fatality. The Sentinel-5P is used for mapping the tropospheric NO
        <sub>
         2
        </sub>
        distribution and the NCEP/NCAR reanalysis for evaluating the atmospheric capability to disperse the pollution. The spatial analysis has been conducted on a regional scale and combined with the number of death cases taken from 66 administrative regions in Italy, Spain, France and Germany. Results show that out of the 4443 fatality cases, 3487 (78%) were in five regions located in north Italy and central Spain. Additionally, the same five regions show the highest NO
        <sub>
         2
        </sub>
        concentrations combined with downwards airflow which prevent an efficient dispersion of air pollution. These results indicate that the long-term exposure to this pollutant may be one of the most important contributors to fatality caused by the COVID-19 virus in these regions and maybe across the whole world.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier B.V. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ogen
        </lastname>
        <forename>
         Yaron
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          The Department of Remote Sensing and Cartography, Institute of Geosciences and Geography, Von-Seckendorff-Platz 4, Room: H4 2.23, Martin-Luther University Halle-Wittenberg, Halle (Saale) 06120, Germany. Electronic address: yaron.ogen@geo.uni-halle.de.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        11
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Sci Total Environ
      </medlineta>
      <nlmuniqueid>
       0330500
      </nlmuniqueid>
      <issnlinking>
       0048-9697
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Nitrogen dioxide (NO(2))
      </keyword>
      <keyword majortopicyn="N">
       Sentinel-5P
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32302812
      </articleid>
      <articleid idtype="pii">
       S0048-9697(20)32121-5
      </articleid>
      <articleid idtype="doi">
       10.1016/j.scitotenv.2020.138605
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32302265
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1524-4571
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Circulation research
       </title>
       <isoabbreviation>
        Circ. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1161/CIRCRESAHA.120.317134
      </elocationid>
      <abstract>
       <abstracttext>
        <b>
         Rationale:
        </b>
        Use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension.
        <b>
         Objective:
        </b>
        To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension.
        <b>
         Methods and Results:
        </b>
        This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [IQR 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [IQR 57-69]; 53.5% men), who were admitted to nine hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. Unadjusted mortality rate was lower in the ACEI/ARB group versus the non-ACEI/ARB group (3.7% vs. 9.8%; P = 0.01). In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted HR, 0.42; 95% CI, 0.19-0.92; P =0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted HR, 0.37; 95% CI, 0.15-0.89; P = 0.03). Further subgroup propensity score-matched analysis indicated that, compared to use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted HR, 0.30; 95%CI, 0.12-0.70; P = 0.01) in COVID-19 patients with hypertension.
        <b>
         Conclusions:
        </b>
        Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Peng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         LiHua
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cai
        </lastname>
        <forename>
         Jingjing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, The Third Xiangya Hospital, Central South University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lei
        </lastname>
        <forename>
         Fang
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qin
        </lastname>
        <forename>
         Juan-Juan
        </forename>
        <initials>
         JJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xie
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Ye-Mao
        </forename>
        <initials>
         YM
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Yan-Ci
        </forename>
        <initials>
         YC
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Xuewei
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Lijin
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xia
        </lastname>
        <forename>
         Meng
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Ming-Ming
        </forename>
        <initials>
         MM
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Wuhan University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cheng
        </lastname>
        <forename>
         Xu
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Xiao
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Eye Center, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Deliang
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Peng
        </lastname>
        <forename>
         Yuanyuan
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Zhongnan Hospital, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ji
        </lastname>
        <forename>
         Yan-Xiao
        </forename>
        <initials>
         YX
        </initials>
        <affiliationinfo>
         <affiliation>
          Animal Biosafety Level-III Laboratory, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         She
        </lastname>
        <forename>
         Zhi-Gang
        </forename>
        <initials>
         ZG
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Yibin
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Anesthesiology and Perioperative Medicine, University of California, Los Angeles, UNITED STATES.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         Qingbo
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Centre for Clinic Pharmacology, William Harvey Research Institute, UNITED KINGDOM.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tan
        </lastname>
        <forename>
         Renfu
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuhan Kanghuashuhai Technology Company, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Haitao
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Hepatopancreatobiliary Surgery, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Jun
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Gastroenterology, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luo
        </lastname>
        <forename>
         Pengcheng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Urology, Wuhan Third Hospital and Tongren Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fu
        </lastname>
        <forename>
         Shouzhi
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Urology, Wuhan Third Hospital and Tongren Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cai
        </lastname>
        <forename>
         Hongbin
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Wuhan Ninth Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ye
        </lastname>
        <forename>
         Ping
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science of Technology, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiao
        </lastname>
        <forename>
         Bing
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Stomatology, Xiantao First People's Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mao
        </lastname>
        <forename>
         Weiming
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          General Surgery, Huanggang Central Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Liming
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          General Surgery, Ezhou Central Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yan
        </lastname>
        <forename>
         Youqin
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Infections Department, Wuhan Seventh Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Mingyu
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Infections Department, Wuhan Ninth Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Manhua
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Xiao-Jing
        </forename>
        <initials>
         XJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Xinghuan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Touyz
        </lastname>
        <forename>
         Rhian M
        </forename>
        <initials>
         RM
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Cardiovascular and Medical Sciences, University of Glasgow, UNITED KINGDOM.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xia
        </lastname>
        <forename>
         Jiahong
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Bing-Hong
        </forename>
        <initials>
         BH
        </initials>
        <affiliationinfo>
         <affiliation>
          Neonatology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Xiaodong
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Tongren Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yuan
        </lastname>
        <forename>
         Yufeng
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rohit
        </lastname>
        <forename>
         Loomba
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          NAFLD Research Center, Division of Gastroenterology and Epidemiology, University of California San Diego, UNITED STATES.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Peter P
        </forename>
        <initials>
         PP
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, University of Ottawa Heart Institute, CANADA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Hongliang
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Circ Res
      </medlineta>
      <nlmuniqueid>
       0047103
      </nlmuniqueid>
      <issnlinking>
       0009-7330
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACEI/ARB
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Pneumonia
      </keyword>
      <keyword majortopicyn="N">
       SARS-COV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32302265
      </articleid>
      <articleid idtype="doi">
       10.1161/CIRCRESAHA.120.317134
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32301198
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1399-3062
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Transplant infectious disease : an official journal of the Transplantation Society
       </title>
       <isoabbreviation>
        Transpl Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Case Report: A Kidney Transplant Patient with Mild COVID-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        e13296
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1111/tid.13296
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus Disease 2019 (COVID-19) is currently a pandemic with a mortality rate of 1-6% in the general population. However, the mortality rate seems to be significantly higher in elderly patients, especially those hospitalized with comorbidities, such as hypertension, diabetes, or coronary artery diseases. Because viral diseases may have atypical presentations in immunosuppressed patients, the course of the disease in the transplant patient population is unknown. Hence, the management of these patients with COVID-19 is an area of interest, and a unique approach is warranted. Here, we report the clinical features and our treatment approach for a kidney transplant patient with a diagnosis of COVID-19. We believe that screening protocols for SARS-Cov-2 should be re-evaluated in patients with solid-organ transplants.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Arpali
        </lastname>
        <forename>
         Emre
        </forename>
        <initials>
         E
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-6172-2398
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Akyollu
        </lastname>
        <forename>
         Basak
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yelken
        </lastname>
        <forename>
         Berna
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tekin
        </lastname>
        <forename>
         Suda
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Disease, Koc University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Turkmen
        </lastname>
        <forename>
         Aydin
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kocak
        </lastname>
        <forename>
         Burak
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D002363">
        Case Reports
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Denmark
      </country>
      <medlineta>
       Transpl Infect Dis
      </medlineta>
      <nlmuniqueid>
       100883688
      </nlmuniqueid>
      <issnlinking>
       1398-2273
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32301198
      </articleid>
      <articleid idtype="doi">
       10.1111/tid.13296
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32298251
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1545-861X
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         69
        </volume>
        <issue>
         15
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        MMWR. Morbidity and mortality weekly report
       </title>
       <isoabbreviation>
        MMWR Morb. Mortal. Wkly. Rep.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.
      </articletitle>
      <pagination>
       <medlinepgn>
        458-464
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.15585/mmwr.mm6915e3
      </elocationid>
      <abstract>
       <abstracttext>
        Since SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in December 2019 (1), approximately 1.3 million cases have been reported worldwide (2), including approximately 330,000 in the United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in the United States, the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) was created using the existing infrastructure of the Influenza Hospitalization Surveillance Network (FluSurv-NET) (4) and the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). This report presents age-stratified COVID-19-associated hospitalization rates for patients admitted during March 1-28, 2020, and clinical data on patients admitted during March 1-30, 2020, the first month of U.S. surveillance. Among 1,482 patients hospitalized with COVID-19, 74.5% were aged ≥50 years, and 54.4% were male. The hospitalization rate among patients identified through COVID-NET during this 4-week period was 4.6 per 100,000 population. Rates were highest (13.8) among adults aged ≥65 years. Among 178 (12%) adult patients with data on underlying conditions as of March 30, 2020, 89.3% had one or more underlying conditions; the most common were hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%). These findings suggest that older adults have elevated rates of COVID-19-associated hospitalization and the majority of persons hospitalized with COVID-19 have underlying medical conditions. These findings underscore the importance of preventive measures (e.g., social distancing, respiratory hygiene, and wearing face coverings in public settings where social distancing measures are difficult to maintain)
        <sup>
         †
        </sup>
        to protect older adults and persons with underlying medical conditions, as well as the general public. In addition, older adults and persons with serious underlying medical conditions should avoid contact with persons who are ill and immediately contact their health care provider(s) if they have symptoms consistent with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) (5). Ongoing monitoring of hospitalization rates, clinical characteristics, and outcomes of hospitalized patients will be important to better understand the evolving epidemiology of COVID-19 in the United States and the clinical spectrum of disease, and to help guide planning and prioritization of health care system resources.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Garg
        </lastname>
        <forename>
         Shikha
        </forename>
        <initials>
         S
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Lindsay
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Whitaker
        </lastname>
        <forename>
         Michael
        </forename>
        <initials>
         M
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         O'Halloran
        </lastname>
        <forename>
         Alissa
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Cummings
        </lastname>
        <forename>
         Charisse
        </forename>
        <initials>
         C
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Holstein
        </lastname>
        <forename>
         Rachel
        </forename>
        <initials>
         R
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Prill
        </lastname>
        <forename>
         Mila
        </forename>
        <initials>
         M
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Chai
        </lastname>
        <forename>
         Shua J
        </forename>
        <initials>
         SJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kirley
        </lastname>
        <forename>
         Pam D
        </forename>
        <initials>
         PD
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Alden
        </lastname>
        <forename>
         Nisha B
        </forename>
        <initials>
         NB
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kawasaki
        </lastname>
        <forename>
         Breanna
        </forename>
        <initials>
         B
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Yousey-Hindes
        </lastname>
        <forename>
         Kimberly
        </forename>
        <initials>
         K
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Niccolai
        </lastname>
        <forename>
         Linda
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Anderson
        </lastname>
        <forename>
         Evan J
        </forename>
        <initials>
         EJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Openo
        </lastname>
        <forename>
         Kyle P
        </forename>
        <initials>
         KP
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Weigel
        </lastname>
        <forename>
         Andrew
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Monroe
        </lastname>
        <forename>
         Maya L
        </forename>
        <initials>
         ML
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Ryan
        </lastname>
        <forename>
         Patricia
        </forename>
        <initials>
         P
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Henderson
        </lastname>
        <forename>
         Justin
        </forename>
        <initials>
         J
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Sue
        </forename>
        <initials>
         S
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Como-Sabetti
        </lastname>
        <forename>
         Kathy
        </forename>
        <initials>
         K
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Lynfield
        </lastname>
        <forename>
         Ruth
        </forename>
        <initials>
         R
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Sosin
        </lastname>
        <forename>
         Daniel
        </forename>
        <initials>
         D
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Torres
        </lastname>
        <forename>
         Salina
        </forename>
        <initials>
         S
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Muse
        </lastname>
        <forename>
         Alison
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Bennett
        </lastname>
        <forename>
         Nancy M
        </forename>
        <initials>
         NM
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Billing
        </lastname>
        <forename>
         Laurie
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Sutton
        </lastname>
        <forename>
         Melissa
        </forename>
        <initials>
         M
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         West
        </lastname>
        <forename>
         Nicole
        </forename>
        <initials>
         N
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Schaffner
        </lastname>
        <forename>
         William
        </forename>
        <initials>
         W
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Talbot
        </lastname>
        <forename>
         H Keipp
        </forename>
        <initials>
         HK
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Aquino
        </lastname>
        <forename>
         Clarissa
        </forename>
        <initials>
         C
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         George
        </lastname>
        <forename>
         Andrea
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Budd
        </lastname>
        <forename>
         Alicia
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Brammer
        </lastname>
        <forename>
         Lynnette
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Langley
        </lastname>
        <forename>
         Gayle
        </forename>
        <initials>
         G
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Hall
        </lastname>
        <forename>
         Aron J
        </forename>
        <initials>
         AJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Fry
        </lastname>
        <forename>
         Alicia
        </forename>
        <initials>
         A
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016425">
        Published Erratum
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       MMWR Morb Mortal Wkly Rep
      </medlineta>
      <nlmuniqueid>
       7802429
      </nlmuniqueid>
      <issnlinking>
       0149-2195
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <coistatement>
      All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Linda Niccolai reports personal fees from Merck outside the submitted work; Evan Anderson reports personal fees from AbbVie and Pfizer, and grants from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron, outside the submitted work; Andrew Weigel reports grants from the Council of State and Territorial Epidemiologists during the conduct of the study; Ruth Lynfield reports that she is the coeditor for a book on public health and an associate editor for American Academy of Pediatrics Report of the Committee of Infectious Diseases (Red Book); Laurie Billing reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; William Schaffner reports personal fees from Pfizer, Roche Diagnostics, and Pepsico outside the submitted work; H. Keipp Talbot reports compensation from Seqiris outside the submitted work; Andrea George reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; Sue Kim reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; Justin Henderson reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; and Clarissa Aquino reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study. No other potential conflicts of interest were disclosed.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298251
      </articleid>
      <articleid idtype="doi">
       10.15585/mmwr.mm6915e3
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32298145
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1941-7705
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Circulation. Cardiovascular quality and outcomes
       </title>
       <isoabbreviation>
        Circ Cardiovasc Qual Outcomes
       </isoabbreviation>
      </journal>
      <articletitle>
       The Role of Data Registries in the Time of COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1161/CIRCOUTCOMES.120.006766
      </elocationid>
      <abstract>
       <abstracttext>
        On April 1, 2020, the confirmed global burden of COVID-19 was more than 900,000 with 46,413 deaths. Despite worldwide calls for social distancing and containment, the incidence of the disease continues to increase. COVID-19 is a respiratory tract infection caused by the novel coronavirus (SARS-CoV2). Preliminary analyses from the Chinese Center for Disease Control and Prevention indicated an overall case fatality rate (CFR) of 2.3%; however the CFR was higher in older adults (14.8% in those 80± years) and 49% of all critical cases. Those with preexisting conditions (cardiovascular disease (CVD), diabetes, chronic respiratory disease, hypertension, and cancer) also had higher CRFs. In the United States, 116 million adults have hypertension, 26 million US adults have diabetes mellitus, 9% have preexisting CVD and may therefore be at greater risk of complications or adverse health outcomes from COVID-19 infection.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alger
        </lastname>
        <forename>
         Heather M
        </forename>
        <initials>
         HM
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Williams Iv
        </lastname>
        <forename>
         Joseph H
        </forename>
        <initials>
         JH
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Walchok
        </lastname>
        <forename>
         Jason G
        </forename>
        <initials>
         JG
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bolles
        </lastname>
        <forename>
         Michele M
        </forename>
        <initials>
         MM
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fonarow
        </lastname>
        <forename>
         Gregg C
        </forename>
        <initials>
         GC
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, University of California Los Angeles, CA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rutan
        </lastname>
        <forename>
         Christine
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Circ Cardiovasc Qual Outcomes
      </medlineta>
      <nlmuniqueid>
       101489148
      </nlmuniqueid>
      <issnlinking>
       1941-7713
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Get With The Guidelines
      </keyword>
      <keyword majortopicyn="N">
       atrial fibrillation
      </keyword>
      <keyword majortopicyn="N">
       coronary artery disease
      </keyword>
      <keyword majortopicyn="N">
       database
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298145
      </articleid>
      <articleid idtype="doi">
       10.1161/CIRCOUTCOMES.120.006766
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32297520
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1522-1555
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         318
        </volume>
        <issue>
         5
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          05
         </month>
         <day>
          01
         </day>
        </pubdate>
       </journalissue>
       <title>
        American journal of physiology. Endocrinology and metabolism
       </title>
       <isoabbreviation>
        Am. J. Physiol. Endocrinol. Metab.
       </isoabbreviation>
      </journal>
      <articletitle>
       Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
      </articletitle>
      <pagination>
       <medlinepgn>
        E587-E588
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1152/ajpendo.00136.2020
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Cadegiani
        </lastname>
        <forename>
         Flávio A
        </forename>
        <initials>
         FA
        </initials>
        <identifier source="ORCID">
         0000-0002-2699-4344
        </identifier>
        <affiliationinfo>
         <affiliation>
          Adrenal and Hypertension Unit, Endocrinology, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Am J Physiol Endocrinol Metab
      </medlineta>
      <nlmuniqueid>
       100901226
      </nlmuniqueid>
      <issnlinking>
       0193-1849
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ARDS
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       coronavirus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32297520
      </articleid>
      <articleid idtype="doi">
       10.1152/ajpendo.00136.2020
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32295322
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        1001-0939
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
       </title>
       <isoabbreviation>
        Zhonghua Jie He He Hu Xi Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province].
      </articletitle>
      <pagination>
       <medlinepgn>
        E042
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.3760/cma.j.cn112147-20200224-00168
      </elocationid>
      <abstract>
       <abstracttext>
        <b>
         Objective:
        </b>
        To analyze the epidemiological characteristics and clinical features of the patients with 2019-nCoV infection in Nanyang City, so as to provide evidence for clinical diagnosis and treatment.
        <b>
         Methods:
        </b>
        The epidemiology, clinical symptoms, atory and radiologic data of 150 patients with 2019-nCoV infection admitted to the designated hospitals in Nanyang City from January 24,2020 to February 16, 2020 were retrospectively analyzed.
        <b>
         Results:
        </b>
        The 150 patients with 2019 nCov infection consisted of 67 men and 83 women, and the median age was 45±16 years; 69 of them were the first generation case,60 of them were the second generation case, 6 of them were the third generation case,the median incubation period of the first generation case was 5.4±2.2 days, and the second generation case was 6.7±3.1 days, and the first-generation cases are the majority in severe patients (69%) . The most common basic disease was hypertension (13 cases, 9%), diabetes (9 cases, 6%), and the most common symptom is fever(142 cases, 95%, 63% showed moderate fever) , cough and sputum(108 cases,72%), fatigue(23 cases,15%), anorexia(20 cases, 13%), headache, diarrhea, muscle soreness, sore throat as the first symptoms. The average time from onset of symptoms to consultation was 4.2±2.2 days for all patients. The changes in peripheral blood cells were mainly lymphonpenia (83 cases, 55%) and eosinophilia (95 cases, 63%), The lymphocyte count of the severe and critically ill patients was more significantly reduced, and some patients had increased myocardial enzymes, mainly LDH (47 cases, 31%), and a few patients had liver function damage, mainly manifested in ALT and AST. High, very few patients have renal impairment. Among the inflammation-related indicators, the main manifestations are increased CRP (66 cases, 43%) and ESR (86 cases, 57%), elevated D-Dimer in 29% of patients. 144 cases have different degrees of infective lesions in chest CT examination, with 30 cases (21%) on one side and 144 cases (79%) on both sides. Morphologically, most of the lesions were patchy ground glass lesions, which could be accompanied by air bronchus signs and some consolidation and paving stone signs. Of the cases showing "white lung", 87% were sever ill or critically ill. After active treatment, 45% of patients were discharged according to discharge standards. 33% of sever and critically ill patients were discharged, 49% of them were degraded hospitalization.The average length of hospitalization was 12±4 days.
        <b>
         Conclusion:
        </b>
        A history of epidemiological exposure, fever, chest CT with signs of pneumonia, normal or decreased WBC, and lymphocytopenia, eosinophilia are the clinical basis for the diagnosis of this disease, and most of the sever patients were the first generation cases. The degree of lymphocytopenia is related to the severity of the disease.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         C
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         X B
        </forename>
        <initials>
         XB
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dai
        </lastname>
        <forename>
         Y
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         X Z
        </forename>
        <initials>
         XZ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         J
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <publicationtypelist>
       <publicationtype ui="D004740">
        English Abstract
       </publicationtype>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhonghua Jie He He Hu Xi Za Zhi
      </medlineta>
      <nlmuniqueid>
       8712226
      </nlmuniqueid>
      <issnlinking>
       1001-0939
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <otherabstract language="chi" type="Publisher">
      <abstracttext>
       <b>
        目的：
       </b>
       分析河南省南阳市2019新型冠状病毒（2019-nCoV）感染患者的流行病学和临床特点，为临床诊治提供依据。
       <b>
        方法：
       </b>
       对2020年1月24日至2020年2月16日在南阳市各定点医院收治的150例2019-nCoV感染患者的流行病学、临床症状、实验室和影像学资料进行回顾性分析，其中男67例，女83例，年龄3~98岁，平均（45±16）岁。
       <b>
        结果：
       </b>
       150例2019-nCoV感染患者中，一代病例69例（69/150，45%），二代病例60例（60/150，40%），三代病例6例（6/150，4%）；一代病例平均潜伏期为（5.4±2.2）d，二代病例平均潜伏期为（6.7±3.1）d，重症患者中一代病例占多数（69%）。患者最常见的基础疾病为高血压（13/150，8%），其次为糖尿病（9/150，6%）；最常见的症状为发热（142/150，95%），多表现为中等发热（38.1~39.0 ℃，90/150，63%），较常见的临床症状为咳嗽咳痰（108/150，72%）、乏力（23/150，15%）、纳差（20/150，13%），少数患者以头痛、腹泻、肌肉酸痛、咽痛为首发症状。所有患者从出现首发症状到就诊平均时间为（4.2±2.2）d。外周血细胞学改变主要为淋巴细胞（83/150，55%）及嗜酸粒细胞减低（95/150，63%），重症及危重症患者淋巴细胞计数降低更显著，部分患者出现心肌酶升高，主要为LDH升高（47/150，31%），少数患者出现肝功能损伤，主要表现为丙氨酸氨基转移酶、天冬氨酸基转移酶升高，极少数患者出现肾功能损伤。炎症相关指标中，主要表现为C反应蛋白（66/150，43%）及ESR（86/150，57%）升高，29%患者D-二聚体升高。所有患者均行胸部CT检查，其中144例存在不同程度的感染性改变，30例累及单肺，114例累及双肺，形态学以斑片状磨玻璃病灶居多，可伴空气支气管征及部分实变及铺路石征；7例影像学呈"白肺"表现，多为重症或危重症患者。经积极治疗，67例患者符合出院标准出院，39例危重症患者中13例出院，19例降级住院，出院患者平均住院时间为（12±4）d。
       <b>
        结论：
       </b>
       有流行病学接触史、发热、胸部CT有肺炎征象及白细胞正常或减少、淋巴细胞减少是诊断本病的临床依据，重症患者多为一代病例，淋巴细胞降低程度与疾病的严重程度呈相关性。.
      </abstracttext>
     </otherabstract>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019 Novel coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Pneumonia
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32295322
      </articleid>
      <articleid idtype="doi">
       10.3760/cma.j.cn112147-20200224-00168
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32294858
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        0376-2491
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         100
        </volume>
        <issue>
         13
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        Zhonghua yi xue za zhi
       </title>
       <isoabbreviation>
        Zhonghua Yi Xue Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [CT imaging analysis of 33 cases with the 2019 novel coronavirus infection].
      </articletitle>
      <pagination>
       <medlinepgn>
        1007-1011
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.3760/cma.j.cn112137-20200203-00182
      </elocationid>
      <abstract>
       <abstracttext>
        <b>
         Objective:
        </b>
        To explore the CT imaging features of the 2019 novel coronavirus (2019-nCoV) infection in order to summarize the imaging characteristics of the disease and improve the ability of imaging diagnosis and early diagnosis of the disease.
        <b>
         Methods:
        </b>
        From January 13, 2020 to January 31, 2020, a total of 33 patients with 2019-nCoV infection diagnosed and treated by Suzhou Fifth People's Hospital were analyzed retrospectively, including 20 males and 13 females, with an average age of (50±12) years, ranging from 20 to 70 years old. There were 3 cases of mild type, 27 cases of common type and 3 cases of severe type.There were 2 cases with hypertension, 1 case with postoperative lung,1 case with diabetes, 1 case with chronic bronchitis, and 1 case with bronchiectasis.SPSS25.0 Chi-square test was used to analyze the distribution of lesions in each lung lobe; SPSS25.0 Spearman correlation coefficient was used to analyze the image score and clinical classification.
        <b>
         Results:
        </b>
        There were 3 cases (9.1%) with normal lung and 30 cases (90.9%) with Novel Coronavirus Pneumonia(COVID-19) of the 2019-nCoV infected patients. In the distribution of COVID-19, 29 cases (87.9%) were involved in bilateral lung and 1 case (3.0%) in unilateral lung. There was no statistically significant difference in the distribution of lesions in each lobe. The correlation coefficient between the degree of lesion distribution and clinical classification was 0.819, and the two were highly correlated.There were 30 cases (90.9%) with subpleural lesions, 17 cases (51.5%) with central lesions. There were many kinds of lesions, 25 cases (75.8%) had ground glass density shadow, 16 cases (48.5%) had consolidation, 12 cases (36.4%) had interstitial change, and 18 cases (54.5%) had interlobular septal thickening. Among the 22 cases, 10 cases had more lesions, 6 cases had no changes and 6 cases had less lesions.
        <b>
         Conclusion:
        </b>
        Most of the patients with 2019-nCoV infection have pulmonary inflammation.CT manifestations include multiple parts, subpleural area or middle and lateral field of lung, ground glass shadow and consolidation, or coexistence. Some cases have pleural thickening or interlobular septal thickening. CT images can indicate the diagnosis of COVID-19 and provide important basis for early detection and disease monitoring.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         R R
        </forename>
        <initials>
         RR
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         Y
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wu
        </lastname>
        <forename>
         M Y
        </forename>
        <initials>
         MY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         J
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ren
        </lastname>
        <forename>
         R
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cao
        </lastname>
        <forename>
         Q L
        </forename>
        <initials>
         QL
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shen
        </lastname>
        <forename>
         X H
        </forename>
        <initials>
         XH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         G Q
        </forename>
        <initials>
         GQ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Second Affiliated Hospital, Soochow University, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         M
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         SYS2020022
        </grantid>
        <agency>
         Suzhou Scientific and Technological Project for Emergency Prevention and Treatment of Novel Coronavirus Infection
        </agency>
        <country>
        </country>
       </grant>
       <grant>
        <grantid>
         Szzx201508
        </grantid>
        <agency>
         Clinical Center for Infectious Diseases
        </agency>
        <country>
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhonghua Yi Xue Za Zhi
      </medlineta>
      <nlmuniqueid>
       7511141
      </nlmuniqueid>
      <issnlinking>
       0376-2491
      </issnlinking>
     </medlinejournalinfo>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000657964">
       COVID-19 diagnostic testing
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000328">
        Adult
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000368">
        Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D019411">
        Clinical Laboratory Techniques
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015897">
        Comorbidity
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000000981">
        diagnostic imaging
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D042241">
        Early Diagnosis
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005260">
        Female
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007249">
        Inflammation
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D008168">
        Lung
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000000981">
        diagnostic imaging
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008297">
        Male
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008875">
        Middle Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000000981">
        diagnostic imaging
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012189">
        Retrospective Studies
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012720">
        Severity of Illness Index
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014057">
        Tomography, X-Ray Computed
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D055815">
        Young Adult
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <otherabstract language="chi" type="Publisher">
      <abstracttext>
       <b>
        目的：
       </b>
       探讨新型冠状病毒（2019-nCoV）感染患者的肺部CT影像表现，总结其影像特征，提高对该病肺部影像诊断能力。
       <b>
        方法：
       </b>
       回顾性分析2020年1月13至31日苏州市第五人民医院诊治的33例2019-nCoV感染患者，男20例、女13例，年龄20~70（50±12）岁。轻型3例，普通型27例，重型3例。其中合并高血压2例，肺部术后、糖尿病、慢性支气管炎、支气管扩张各1例。运用SPSS 25.0软件对各肺叶分布及分布范围与临床相关性进行统计学分析。
       <b>
        结果：
       </b>
       2019-nCoV感染者肺部无异常3例（9.1%），新型冠状病毒肺炎（COVID-19）30例（90.9%）。COVID-19在分布上累及双肺29例（87.9%），累及单侧1例（3.0%）。病变在各肺叶分布的差异无统计学意义，病变分布范围与临床分型之间相关系数为0.819，两者具有高度相关。胸膜下区病变30例（90.9%），其中合并中央区同时存在17例（51.5%）。病变表现为多种病变及合并存在，磨玻璃密度影25例（75.8%），实变16例（48.5%），间质改变12例（36.4%），小叶间隔增厚18例（54.5%）。22例复查者，病变增多10例，病变无变化6例，病变减少6例。
       <b>
        结论：
       </b>
       2019-nCoV感染者多有肺部炎症，CT表现为多部位、胸膜下区或外中带多见、磨玻璃密度和实变多见或共存；部分合并胸膜增厚或小叶间隔增厚。CT影像能够提示COVID-19诊断，对早期发现和病情监测提供重要依据。.
      </abstracttext>
     </otherabstract>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       Lung
      </keyword>
      <keyword majortopicyn="N">
       Pneumonia
      </keyword>
      <keyword majortopicyn="N">
       Tomography, X-ray computed
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32294858
      </articleid>
      <articleid idtype="doi">
       10.3760/cma.j.cn112137-20200203-00182
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32293003
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1755-3245
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cardiovascular research
       </title>
       <isoabbreviation>
        Cardiovasc. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       cvaa097
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/cvr/cvaa097
      </elocationid>
      <abstract>
       <abstracttext>
        Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic.
       </abstracttext>
       <copyrightinformation>
        Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kreutz
        </lastname>
        <forename>
         Reinhold
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Algharably
        </lastname>
        <forename>
         Engi Abd El-Hady
        </forename>
        <initials>
         EAE
        </initials>
        <affiliationinfo>
         <affiliation>
          Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Azizi
        </lastname>
        <forename>
         Michel
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Université Paris-Descartes; AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE; INSERM, CIC1418, Paris, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dobrowolski
        </lastname>
        <forename>
         Piotr
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guzik
        </lastname>
        <forename>
         Tomasz
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Cardiovascular &amp; Medical Sciences BHF Glasgow Cardiovascular Research Centre; Glasgow, UK and Jagiellonian University, Collegium Medicum, Krakow, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Januszewicz
        </lastname>
        <forename>
         Andrzej
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Persu
        </lastname>
        <forename>
         Alexandre
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Prejbisz
        </lastname>
        <forename>
         Aleksander
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Riemer
        </lastname>
        <forename>
         Thomas Günther
        </forename>
        <initials>
         TG
        </initials>
        <affiliationinfo>
         <affiliation>
          Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Ji-Guang
        </forename>
        <initials>
         JG
        </initials>
        <affiliationinfo>
         <affiliation>
          The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Burnier
        </lastname>
        <forename>
         Michel
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Cardiovasc Res
      </medlineta>
      <nlmuniqueid>
       0077427
      </nlmuniqueid>
      <issnlinking>
       0008-6363
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       Angiotensin
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       Cardiovascular
      </keyword>
      <keyword majortopicyn="Y">
       Hypertension
      </keyword>
      <keyword majortopicyn="Y">
       Lung
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32293003
      </articleid>
      <articleid idtype="pii">
       5819836
      </articleid>
      <articleid idtype="doi">
       10.1093/cvr/cvaa097
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32291526
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1534-3170
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         22
        </volume>
        <issue>
         5
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Current cardiology reports
       </title>
       <isoabbreviation>
        Curr Cardiol Rep
       </isoabbreviation>
      </journal>
      <articletitle>
       Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
      </articletitle>
      <pagination>
       <medlinepgn>
        31
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s11886-020-01291-4
      </elocationid>
      <abstract>
       <abstracttext label="PURPOSE OF REVIEW">
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.
       </abstracttext>
       <abstracttext label="RECENT FINDINGS">
        Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated. Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rico-Mesa
        </lastname>
        <forename>
         Juan Simon
        </forename>
        <initials>
         JS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         White
        </lastname>
        <forename>
         Averi
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Anderson
        </lastname>
        <forename>
         Allen S
        </forename>
        <initials>
         AS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Curr Cardiol Rep
      </medlineta>
      <nlmuniqueid>
       100888969
      </nlmuniqueid>
      <issnlinking>
       1523-3782
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACE2 receptor
      </keyword>
      <keyword majortopicyn="Y">
       ACEI
      </keyword>
      <keyword majortopicyn="Y">
       ARB
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       SARS-COV 2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291526
      </articleid>
      <articleid idtype="doi">
       10.1007/s11886-020-01291-4
      </articleid>
      <articleid idtype="pii">
       10.1007/s11886-020-01291-4
      </articleid>
      <articleid idtype="pmc">
       PMC7154066
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Ther. 2010 Oct;128(1):119-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20599443
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Compr Physiol. 2014 Jul;4(3):1201-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24944035
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Res. 2017 Nov;125(Pt A):21-38
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28619367
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Allergy. 2020 Feb 19;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32077115
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 May;92(5):491-494
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32056249
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2015 Jan;28(1):15-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24842388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32120458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Saudi Med. 2016 Jan-Feb;36(1):78-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26922692
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trop Med Int Health. 2020 Mar;25(3):278-280
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32052514
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2005 May 24;111(20):2605-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15897343
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2020 Feb 28;368:m810
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32111649
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Feb 24;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105632
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Conn Med. 1965 Oct;29(10):710-1
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         4284109
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32164092
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32291399
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1530-0285
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
       </title>
       <isoabbreviation>
        Mod. Pathol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1038/s41379-020-0536-x
      </elocationid>
      <abstract>
       <abstracttext>
        Data on pathologic changes of the 2019 novel coronavirus disease (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed postmortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia. The patients' ages ranged from 59 to 81, including three males and one female. Each patient had at least one underlying disease, including immunocompromised status (chronic lymphocytic leukemia and renal transplantation) or other conditions (cirrhosis, hypertension, and diabetes). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes, all components of diffuse alveolar damage. Consolidation by fibroblastic proliferation with extracellular matrix and fibrin forming clusters in airspaces is evident. In one patient, the consolidation consists of abundant intra-alveolar neutrophilic infiltration, consistent with superimposed bacterial bronchopneumonia. The liver exhibits mild lobular infiltration by small lymphocytes, and centrilobular sinusoidal dilation. Patchy necrosis is also seen. The heart shows only focal mild fibrosis and mild myocardial hypertrophy, changes likely related to the underlying conditions. In conclusion, the postmortem examinations show advanced diffuse alveolar damage, as well as superimposed bacterial pneumonia in some patients. Changes in the liver and heart are likely secondary or related to the underlying diseases.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tian
        </lastname>
        <forename>
         Sufang
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiong
        </lastname>
        <forename>
         Yong
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Huan
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Niu
        </lastname>
        <forename>
         Li
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Jianchun
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liao
        </lastname>
        <forename>
         Meiyan
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China. liaomy@whu.edu.cn.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiao
        </lastname>
        <forename>
         Shu-Yuan
        </forename>
        <initials>
         SY
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-0484-932X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. syxiao@uchicago.edu.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, University of Chicago Medicine, Chicago, IL, 60637, USA. syxiao@uchicago.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Mod Pathol
      </medlineta>
      <nlmuniqueid>
       8806605
      </nlmuniqueid>
      <issnlinking>
       0893-3952
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291399
      </articleid>
      <articleid idtype="doi">
       10.1038/s41379-020-0536-x
      </articleid>
      <articleid idtype="pii">
       10.1038/s41379-020-0536-x
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32291207
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1874-1754
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of cardiology
       </title>
       <isoabbreviation>
        Int. J. Cardiol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0167-5273(20)31115-3
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijcard.2020.03.087
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
        A novel coronavirus disease (COVID-19) in Wuhan has caused an outbreak and become a major public health issue in China and great concern from international community. Myocarditis and myocardial injury were suspected and may even be considered as one of the leading causes for death of COVID-19 patients. Therefore, we focused on the condition of the heart, and sought to provide firsthand evidence for whether myocarditis and myocardial injury were caused by COVID-19.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        We enrolled patients with confirmed diagnosis of COVID-19 retrospectively and collected heart-related clinical data, mainly including cardiac imaging findings, laboratory results and clinical outcomes. Serial tests of cardiac markers were traced for the analysis of potential myocardial injury/myocarditis.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        112 COVID-19 patients were enrolled in our study. There was evidence of myocardial injury in COVID-19 patients and 14 (12.5%) patients had presented abnormalities similar to myocarditis. Most of patients had normal levels of troponin at admission, that in 42 (37.5%) patients increased during hospitalization, especially in those that died. Troponin levels were significantly increased in the week preceding the death. 15 (13.4%) patients have presented signs of pulmonary hypertension. Typical signs of myocarditis were absent on echocardiography and electrocardiogram.
       </abstracttext>
       <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
        The clinical evidence in our study suggested that myocardial injury is more likely related to systemic consequences rather than direct damage by the 2019 novel coronavirus. The elevation in cardiac markers was probably due to secondary and systemic consequences and can be considered as the warning sign for recent adverse clinical outcomes of the patients.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020. Published by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Deng
        </lastname>
        <forename>
         Qing
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Bo
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Yao
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Hao
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Xiaoyang
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Wei
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cheng
        </lastname>
        <forename>
         Yuting
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yan
        </lastname>
        <forename>
         Jie
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ping
        </lastname>
        <forename>
         Haiqin
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Qing
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Echo Lab, Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan 430060, China. Electronic address: qingzhou.wh.edu@hotmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Cardiol
      </medlineta>
      <nlmuniqueid>
       8200291
      </nlmuniqueid>
      <issnlinking>
       0167-5273
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Cardiac marker
      </keyword>
      <keyword majortopicyn="N">
       Myocardial injury
      </keyword>
      <keyword majortopicyn="N">
       Myocarditis
      </keyword>
      <keyword majortopicyn="N">
       Novel coronavirus
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest The authors report no relationships that could be construed as a conflict of interest.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        04
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        28
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291207
      </articleid>
      <articleid idtype="pii">
       S0167-5273(20)31115-3
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijcard.2020.03.087
      </articleid>
      <articleid idtype="pmc">
       PMC7141178
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):514-523
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986261
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Nov 28;503(7477):535-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24172901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2002 Jun 20;417(6891):822-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12075344
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur J Clin Invest. 2009 Jul;39(7):618-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19453650
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Semin Immunopathol. 2017 Jul;39(5):529-539
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28466096
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Rep. 2017 Jul 26;7(1):6610
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28747765
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25559473
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Future Med Chem. 2017 Feb;9(2):169-178
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28128003
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Heart J. 2016 Jan 1;37(1):67-119
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26320113
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2020 Feb 11;141(6):e69-e92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31902242
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20620859
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22390970
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32290680
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2047-4881
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        European journal of preventive cardiology
       </title>
       <isoabbreviation>
        Eur J Prev Cardiol
       </isoabbreviation>
      </journal>
      <articletitle>
       Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.
      </articletitle>
      <pagination>
       <medlinepgn>
        2047487320918421
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1177/2047487320918421
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sarzani
        </lastname>
        <forename>
         Riccardo
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Giulietti
        </lastname>
        <forename>
         Federico
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pentima
        </lastname>
        <forename>
         Chiara Di
        </forename>
        <initials>
         CD
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Giordano
        </lastname>
        <forename>
         Piero
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Spannella
        </lastname>
        <forename>
         Francesco
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Eur J Prev Cardiol
      </medlineta>
      <nlmuniqueid>
       101564430
      </nlmuniqueid>
      <issnlinking>
       2047-4873
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32290680
      </articleid>
      <articleid idtype="doi">
       10.1177/2047487320918421
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32286607
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2055-6845
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        European heart journal. Cardiovascular pharmacotherapy
       </title>
       <isoabbreviation>
        Eur Heart J Cardiovasc Pharmacother
       </isoabbreviation>
      </journal>
      <articletitle>
       Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       pvaa030
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/ehjcvp/pvaa030
      </elocationid>
      <abstract>
       <abstracttext>
        Since December 2019, a new coronavirus, named SARS-CoV-2, has spread globally, affecting &gt;200 000 people worldwide with the so-called COVID-19 disease. The scientific community is actively and constantly working to identify the mechanisms involved in the diffusion of this virus and the pathogenesis of the infection, with its most frequent and severe complication, namely interstitial pneumonia. To date, SARS-CoV-2 is known to enter the host cells via the angiotensin-converting enzyme 2 protein. For this reason, the hypothesis that drugs capable of increasing the expression of this protein may have a role in the spread of the virus and in the symptomatology of affected patients has taken hold. The purpose of this Editorial is to briefly show the evidence currently available in this regard and to provide ideas for future research.
       </abstracttext>
       <copyrightinformation>
        Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Battistoni
        </lastname>
        <forename>
         Allegra
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Volpe
        </lastname>
        <forename>
         Massimo
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          IRCCS Neuromed, Pozzilli, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Eur Heart J Cardiovasc Pharmacother
      </medlineta>
      <nlmuniqueid>
       101669491
      </nlmuniqueid>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Hypertension
      </keyword>
      <keyword majortopicyn="N">
       RAS system
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        19
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32286607
      </articleid>
      <articleid idtype="pii">
       5819835
      </articleid>
      <articleid idtype="doi">
       10.1093/ehjcvp/pvaa030
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32286245
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1437-4331
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical chemistry and laboratory medicine
       </title>
       <isoabbreviation>
        Clin. Chem. Lab. Med.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1515/cclm-2020-0369
      </elocationid>
      <elocationid eidtype="pii" validyn="Y">
       /j/cclm.ahead-of-print/cclm-2020-0369/cclm-2020-0369.xml
      </elocationid>
      <abstract>
       <abstracttext>
        Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness. In this study we aimed to evaluate the discriminative ability of hematologic, biochemical and immunologic biomarkers in patients with and without the severe or fatal forms of COVID-19. Methods An electronic search in Medline (PubMed interface), Scopus, Web of Science and China National Knowledge Infrastructure (CNKI) was performed, to identify studies reporting on laboratory abnormalities in patients with COVID-19. Studies were divided into two separate cohorts for analysis: severity (severe vs. non-severe and mortality, i.e. non-survivors vs. survivors). Data was pooled into a meta-analysis to estimate weighted mean difference (WMD) with 95% confidence interval (95% CI) for each laboratory parameter. Results A total number of 21 studies was included, totaling 3377 patients and 33 laboratory parameters. While 18 studies (n = 2984) compared laboratory findings between patients with severe and non-severe COVID-19, the other three (n = 393) compared survivors and non-survivors of the disease and were thus analyzed separately. Patients with severe and fatal disease had significantly increased white blood cell (WBC) count, and decreased lymphocyte and platelet counts compared to non-severe disease and survivors. Biomarkers of inflammation, cardiac and muscle injury, liver and kidney function and coagulation measures were also significantly elevated in patients with both severe and fatal COVID-19. Interleukins 6 (IL-6) and 10 (IL-10) and serum ferritin were strong discriminators for severe disease. Conclusions Several biomarkers which may potentially aid in risk stratification models for predicting severe and fatal COVID-19 were identified. In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Henry
        </lastname>
        <forename>
         Brandon Michael
        </forename>
        <initials>
         BM
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         de Oliveira
        </lastname>
        <forename>
         Maria Helena Santos
        </forename>
        <initials>
         MHS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Statistics, Federal University of Parana, Curitiba, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Benoit
        </lastname>
        <forename>
         Stefanie
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Plebani
        </lastname>
        <forename>
         Mario
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Laboratory Medicine, University Hospital of Padova, Padova, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lippi
        </lastname>
        <forename>
         Giuseppe
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University Hospital of Verona, Piazzale LA Scuro, 37134 Verona, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Chem Lab Med
      </medlineta>
      <nlmuniqueid>
       9806306
      </nlmuniqueid>
      <issnlinking>
       1434-6621
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       clinical chemistry
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32286245
      </articleid>
      <articleid idtype="doi">
       10.1515/cclm-2020-0369
      </articleid>
      <articleid idtype="pii">
       /j/cclm.ahead-of-print/cclm-2020-0369/cclm-2020-0369.xml
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32283980
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1942-7522
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Ear, nose, &amp; throat journal
       </title>
       <isoabbreviation>
        Ear Nose Throat J
       </isoabbreviation>
      </journal>
      <articletitle>
       Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms.
      </articletitle>
      <pagination>
       <medlinepgn>
        145561320920762
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1177/0145561320920762
      </elocationid>
      <abstract>
       <abstracttext label="AIM" nlmcategory="UNASSIGNED">
        Pharyngodynia, nasal congestion, rhinorrhea, smell, and taste dysfunctions could be the presenting symptoms of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2. The aim was to perform a systematic review of current evidences on clinical presentation of COVID-19, focusing on upper airway symptoms in order to help otolaryngologists identifying suspected cases.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="UNASSIGNED">
        We searched PubMed and Web of Science electronic databases.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="UNASSIGNED">
        We included 5 retrospective clinical studies for a total of 1556 hospitalized patients with COVID-19, 57.5% were male and mean age was 49.1 years. Pooled data revealed that pharyngodynia was present in 12.4% of patients, nasal congestion in 3.7%, and rhinorrhea was rare. No reports on COVID-19 and olfactory/gustative disorders matched inclusion criteria but preliminary evidences suggested they could be present. Common symptoms were fever (85.6%), cough (68.7%), and fatigue (39.4%). Frequent comorbidities were hypertension (17.4%), diabetes (3.8%), and coronary heart disease (3.8%); 83% of patients had alterations on chest computed tomography that were bilateral in 89.5% of cases. Ground-glass opacity was the most common finding (50%). Lymphopenia (77.2%) and leucopenia (30.1%) were common. Critical cases with complications were 9%, intensive care unit admission was required in 7.3%, invasive ventilation in 3.4%, and mortality was 2.4%.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="UNASSIGNED">
        Otolaryngologists should know that pharyngodynia, nasal congestion, olfactory, and gustative disorders could be the presenting symptoms of COVID-19. Clinical presentation together with radiological and laboratory findings could help to identify suspected cases.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Lovato
        </lastname>
        <forename>
         Andrea
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-0369-1751
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Neurosciences, University of Padova, Audiology Unit at Treviso Hospital, Treviso, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         de Filippis
        </lastname>
        <forename>
         Cosimo
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Neurosciences, University of Padova, Audiology Unit at Treviso Hospital, Treviso, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Ear Nose Throat J
      </medlineta>
      <nlmuniqueid>
       7701817
      </nlmuniqueid>
      <issnlinking>
       0145-5613
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       nasal congestion
      </keyword>
      <keyword majortopicyn="N">
       pharyngodynia
      </keyword>
      <keyword majortopicyn="N">
       smell
      </keyword>
      <keyword majortopicyn="N">
       taste
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32283980
      </articleid>
      <articleid idtype="doi">
       10.1177/0145561320920762
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32279908
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1873-5487
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          04
         </day>
        </pubdate>
       </journalissue>
       <title>
        Archives of medical research
       </title>
       <isoabbreviation>
        Arch. Med. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0188-4409(20)30378-7
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.arcmed.2020.03.011
      </elocationid>
      <abstract>
       <abstracttext>
        In the recent coronavirus disease (COVID-19) outbreak, a higher proportion of patients with severe disease were found in older persons with comorbidities. This observation has been related to the use of drugs that can increase the cellular expression of angiotensin-converting enzyme 2 (ACE2) that has been recognized as target to which the virus bind to cells. Although this hypothesis is possible, it may also have other explanations which are discussed.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gracia-Ramos
        </lastname>
        <forename>
         Abraham Edgar
        </forename>
        <initials>
         AE
        </initials>
        <affiliationinfo>
         <affiliation>
          Departamento de Medicina Interna, Hospital General, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico. Electronic address: dr.gracia.dmm@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        04
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Arch Med Res
      </medlineta>
      <nlmuniqueid>
       9312706
      </nlmuniqueid>
      <issnlinking>
       0188-4409
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus infections
      </keyword>
      <keyword majortopicyn="N">
       Diabetes mellitus
      </keyword>
      <keyword majortopicyn="N">
       Hypertension
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32279908
      </articleid>
      <articleid idtype="pii">
       S0188-4409(20)30378-7
      </articleid>
      <articleid idtype="doi">
       10.1016/j.arcmed.2020.03.011
      </articleid>
      <articleid idtype="pmc">
       PMC7128661
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        BMC Public Health. 2018 May 2;18(1):574
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29716568
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2018 May 29;137(22):2344-2356
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29449338
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2014 Feb;27(2):252-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24108862
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Am Coll Cardiol. 2019 Jun 25;73(24):3135-3147
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31221263
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Aging Dis. 2018 Feb 1;9(1):143-150
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29392089
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Diabetes. 2015 Mar;7(2):166-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24809622
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2013 Sep 4;310(9):948-59
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24002281
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2015 Sep 5;386(9997):995-1007
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26049252
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32277836
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Electronic">
        1424-3997
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         150
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Swiss medical weekly
       </title>
       <isoabbreviation>
        Swiss Med Wkly
       </isoabbreviation>
      </journal>
      <articletitle>
       Benign COVID-19 in an immunocompromised cancer patient -  the case of a married couple.
      </articletitle>
      <pagination>
       <medlinepgn>
        w20246
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.4414/smw.2020.20246
      </elocationid>
      <elocationid eidtype="pii" validyn="Y">
       Swiss Med Wkly. 2020;150:w20246
      </elocationid>
      <abstract>
       <abstracttext>
        Respiratory failure in COVID-19 is a common feature in fatal cases and has been considered as a failure of the immune system to control the virus. Here we report the case of COVID-19 affecting an immunocompromised women and her presumably immunocompetent spouse. A married couple (age 60 years) was simultaneously admitted to the emergency department on 10 March 2020 because of dyspnoea and fever, consistent with COVID-19. The wife (patient 1) was partially immunocompromised as a consequence of a recently started chemotherapy with fulvestrant and abemaciclid for recurring breast cancer, her husband (patient 2) had been healthy except for a history of controlled arterial hypertension. Both patients were treated with darunavir/cobicistat and hydroxychloroquine. The clinical course of the immunocompromised partner was benign, without need of intensive care. She was able to leave the hospital on day 6 after admission. In contrast, her husband needed intensive care and his recovery was slow, although eventually successful too. These findings suggest that the course of COVID-19 is not necessarily ominous in the presence of a compromised immune response and tend to reinforce the emerging therapeutic concepts of a controlled mitigation of the immune cascade following SARS CoV-2 infection.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Spezzani
        </lastname>
        <forename>
         Valentina
        </forename>
        <initials>
         V
        </initials>
        <affiliationinfo>
         <affiliation>
          Family Medicine, Unità Sanitaria Locale del Servizio Sanitario Regionale Emilia-Romagna, Modena, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Piunno
        </lastname>
        <forename>
         Alessio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Radiology, Ospedale di Sassuolo (Prov. Modena), Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Iselin
        </lastname>
        <forename>
         Hans-Ulrich
        </forename>
        <initials>
         HU
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant for Interprofessional Communication, Riehen, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D002363">
        Case Reports
       </publicationtype>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        11
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Swiss Med Wkly
      </medlineta>
      <nlmuniqueid>
       100970884
      </nlmuniqueid>
      <issnlinking>
       0036-7672
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000900">
        Anti-Bacterial Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        4QWG6N8QKH
       </registrynumber>
       <nameofsubstance ui="D006886">
        Hydroxychloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        LW2E03M5PG
       </registrynumber>
       <nameofsubstance ui="D000069547">
        Cobicistat
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        YO603Y8113
       </registrynumber>
       <nameofsubstance ui="D000069454">
        Darunavir
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000900">
        Anti-Bacterial Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D001943">
        Breast Neoplasms
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000150">
        complications
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000069547">
        Cobicistat
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003422">
        Critical Care
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000069454">
        Darunavir
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004417">
        Dyspnea
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004636">
        Emergency Service, Hospital
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005260">
        Female
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005334">
        Fever
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006886">
        Hydroxychloroquine
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007121">
        Immunocompetence
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016867">
        Immunocompromised Host
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008297">
        Male
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008875">
        Middle Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D009364">
        Neoplasm Recurrence, Local
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018454">
        Spouses
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016896">
        Treatment Outcome
       </descriptorname>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277836
      </articleid>
      <articleid idtype="doi">
       10.4414/smw.2020.20246
      </articleid>
      <articleid idtype="pii">
       Swiss Med Wkly. 2020;150:w20246
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277367
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1434-9949
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical rheumatology
       </title>
       <isoabbreviation>
        Clin. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s10067-020-05073-9
      </elocationid>
      <abstract>
       <abstracttext>
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points• Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.• Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.• Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5035-7396
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. durgapmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agarwal
        </lastname>
        <forename>
         Vikas
        </forename>
        <initials>
         V
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4508-1233
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gasparyan
        </lastname>
        <forename>
         Armen Yuri
        </forename>
        <initials>
         AY
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8749-6018
        </identifier>
        <affiliationinfo>
         <affiliation>
          Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zimba
        </lastname>
        <forename>
         Olena
        </forename>
        <initials>
         O
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4188-8486
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Rheumatol
      </medlineta>
      <nlmuniqueid>
       8211469
      </nlmuniqueid>
      <issnlinking>
       0770-3198
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Epidemiology
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hypothesis
      </keyword>
      <keyword majortopicyn="N">
       Immunity
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       Vaccines
      </keyword>
      <keyword majortopicyn="N">
       Vitamin D
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277367
      </articleid>
      <articleid idtype="doi">
       10.1007/s10067-020-05073-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s10067-020-05073-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>